Fabry Disease due to NM_000169.3(GLA):c.1082del;p.(Gly361Aspfs*30), variant: a family report
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2026.233969Palabras clave:
Fabry disease, Lysosomal storage disorder, Genotype, PhenotypeResumen
Fabry disease (FD) is a lysosomal storage disorder caused by pathogenic variants in the GLA gene, leading to a deficiency in alpha-galactosidase A (α-GalA) enzyme activity and the accumulation of globotriaosylceramide (Gb3). This condition results in progressive organ damage, especially to the
kidneys, heart, skin, and nervous system. Here, we report a pathogenic variant NM_000169.3(-GLA):c.1082del; p.(Gly361Aspfs*30), in a Brazilian family, adding to the growing understanding of the genotype-phenotype correlation in FD. A 51-year-old male proband with end-stage kidney disease
and a family history of hypertension and chronic kidney disease was diagnosed with fabry disease after genetic analysis identified the GLA variant. His α-GalA enzyme activity was significantly
reduced, and Gb3 levels were elevated. Clinical manifestations included left ventricular hypertrophy, retinal arteriolar sclerosis, and cerebrovascular lesions. Genetic testing revealed that four of his six siblings carried the same pathogenic variant, with varying clinical presentations. Male carriers exhibited typical FD symptoms, while female carriers showed milder manifestations, including retinal vascular changes and mild cardiac abnormalities. This variant adds to the clinical variability observed in FD and highlights the importance of genetic testing for early diagnosis and management. This case highlights the need for further research into the genotype-phenotype correlation to improve diagnosis and treatment strategies for affected individuals, particularly in families with unexplained renal or
cardiovascular disease.
Descargas
Referencias
1. Dinu IR, Firu SG. Fabry disease- current data and therapeutic approaches. Rom J Morphol Embryol 2021;62(1):5-11.
2.Michaud M, Mauhin W, Belmatoug N, Bedreddine N, Garnotel R, Catros F, et al. Fabry disease: A review. Rev Med Interne 2021;42(2):110-9.
3. Bernardes TP, Foresto RD, Kirsztajn GM. Fabry disease: genetics, pathology, and treatment. Rev Assoc Med Bras. 2020;66(1):10-6.
4. Abensur H. Doença de Fabry: pacientes em risco no Brasil!. Braz J Nephrol. 2021;43(1):5-6.
5. Maier EM, Osterrieder S, Whybra C, Ries M, Gal A, Beck M, et al. Disease manifestations and X inactivation in heterozygous females with Fabry disease. Acta Paediatr Suppl. 2006;95(451):30-8.
6. Fernández A, Politei J. Cardiac Manifestation of Fabry Disease: From Hypertrophic Cardiomyopathy to Early Diagnosis and Treatment in Patients Without Left Ventricular Hypertrophy. J inborn errors metab screen. 2016;4:1-9.
7. Germain DP, Oliveria JP, Bichet DG, Yoo HW, Hopkin RJ, Lemay R, et al. Use of a rare disease registry for establishing phenotypic classification of previously unassigned GLA variants: a consensus classification system by a multispecialty Fabry disease genotype–phenotype workgroup. J Med Genet. 2020;57(8):542-51.
8. Mehta A, Hughes DA. Fabry Disease. 2002 Aug 5 [Updated 2024 Apr 11]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025
9. Pan X, Ouyang Y, Wang Z, Ren H, Shen P, Wang W, et al. Genotype: A Crucial but Not Unique Factor Affecting the Clinical Phenotypes in Fabry Disease. PLoS ONE. 2016;11(8): e0161330.
10. Mishra V, Banerjee A, Gandhi AB, Kaleem I, Alexander J, Hisbulla M, et al. Stroke and Fabry Disease: A Review of Literature. Cureus. 2020;12:e12083.
11. Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91(2):210-4.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Anna Leticia Martins Maciel Baumel, Dora Pedroso Kowacs, Rafaela Gabriele Nascimento da Silveira, Eduardo Iwankiw dos Santos, Gina Elizabeth Moreno Gordon, René Scalet Santos Neto

Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.



